These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1676 related articles for article (PubMed ID: 24604920)

  • 1. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
    Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA
    Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.
    Machado M; Einarson TR
    J Clin Pharm Ther; 2010 Apr; 35(2):177-88. PubMed ID: 20456736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
    Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials.
    Chen Y; Li J; Liao M; He Y; Dang C; Yu J; Xing S; Zeng J
    Int Clin Psychopharmacol; 2024 May; 39(3):163-173. PubMed ID: 37781768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
    Machado M; Iskedjian M; Ruiz I; Einarson TR
    Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.
    Sobieraj DM; Martinez BK; Hernandez AV; Coleman CI; Ross JS; Berg KM; Steffens DC; Baker WL
    J Am Geriatr Soc; 2019 Aug; 67(8):1571-1581. PubMed ID: 31140587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Effects of Antidepressants with Different Mechanisms of Action on Efficacy, Cognitive Functions and Side Effects.
    Erdoğan Ç; Özdemir Rezaki H; Koçak OM; Buturak ŞV
    Turk Psikiyatri Derg; 2020; 31(2):90-98. PubMed ID: 32594496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
    Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
    Maddukuri RK; Hema C; Sri Tejaswi K; Venkata Mounika M; Vegesana BP
    Asian J Psychiatr; 2021 Nov; 65():102866. PubMed ID: 34592623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of early improvement of major depressive disorder to antidepressant medication in adolescents with radiomics analysis after ComBat harmonization based on multiscale structural MRI.
    Ma H; Zhang D; Wang Y; Ding Y; Yang J; Li K
    BMC Psychiatry; 2023 Jun; 23(1):466. PubMed ID: 37365541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.